Platform Application: Prime Editor Delivery
Genetic Diseases
Pre-clinicalActive
Key Facts
About NTrans Technologies
NTrans Technologies is a private, pre-revenue biotech company pioneering a non-viral delivery platform for cell and gene therapies. Its core technology harnesses macropinocytosis, a natural cellular mechanism, to efficiently and safely deliver gene-editing complexes (RNPs) into patient cells ex vivo, with a focus on enhancing CAR-T therapies and other genetic medicines. The company, which is GMP-ready and emphasizes low manufacturing costs and high scalability, is supported by non-dilutive funding and strategic collaborations within the Dutch life sciences ecosystem. NTrans aims to solve key delivery challenges to unlock the full potential of next-generation genetic medicines.
View full company profileTherapeutic Areas
Other Genetic Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| Gene Therapy/Gene Editing Program | Tiba Biotech | Discovery |
| Non-Viral Gene Delivery Platform | DNA Nanobots | Pre-clinical |
| Platform Application: Base Editor Delivery | NTrans Technologies | Pre-clinical |